WASHINGTON (Legal Newsline) — The Federal Trade Commission (FTC) has approved, after a public comment period ended, a final order settling charges that U.S. Renal Care Inc.’s $640 million acquisition of competitor DSI Renal from parent company Dialysis Parent LLC would be anti-competitive.
U.S. Renal Care is a national kidney-dialysis chain. Rangers Renal Holdings LP, its parent company, and Dialysis Parent LLC must divest three DSI Renal outpatient dialysis clinics in Laredo to a company called Satellite Healthcare Inc.
The FTC approved the final order by a vote of 4-0.
Organizations in this Story
U.S. Federal Trade Commission
600 Pennsylvania Ave NW
Washington, DC 20580
Get notified the next time we write about
U.S. Federal Trade Commission !